Ondine Biomedical Inc (AIM:OBI) has made a key senior appointment who will lead the commercialisation of the company’s breakthrough antimicrobial technology.
Charles Young is joining the group as its vice-president of sales and marketing in North America.
He is joining from Professional Disposables International (PDI), a market leader in products that help reduce preventable infections.
He brings with him 30 years of experience in business development and in previous roles he administered budgets in excess of $100mln.
Young will be responsible for the rollout of Ondine’s pioneering Steriwave technology, which uses a process called photodisinfection to rapidly destroy pathogens.
Ondine chief executive Carolyn Cross said Young initially focus on sales activity in Canada while also making preparations to enter the US, where the device is being fast-tracked by the Food & Drug Administration.
“We are delighted that Charles will lead our commercial efforts as he will be bringing his vast commercial experience, deep industry relationships, and considerable expertise in infection control to the Ondine team,” she added.